Skinvisible’s Subsidiary Kintari Announces Network Marketing Expert Dean Aldridge as Master Distributor
Kintari Launching Patented Skin Care Product Line
Las Vegas, NV– October 29, 2014 – Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) – through its wholly owned subsidiary Kintari International Inc., makers of patented “Youth Renewed” skin care products – is pleased to announce the selection of R. Dean Aldridge in the key role of Master Distributor. Dean will spearhead distributor expansion and development globally.
“We are very pleased to have Dean Aldridge, a world class marketer and sales leader, as our Master Distributor for Kintari,” said Terry Howlett, President of Kintari. “The Master Distributor plays a crucial role in the upward trajectory of the number of distributors that join Kintari and the sales they produce. Dean has exactly the skills and experience to make Kintari a huge success.” He added, “Dean has proven his skills over the past fifteen years in the network marketing industry. He is a multiple award winner and has climbed to the highest level of every company he has been associated with. Dean is often referred to as one of the top recruiters as well as one of the best relationship builders our industry has seen. His expertise has taken him to the top echelons of financial rewards and is touted as one of network marketing’s most distinguished international leaders.”
“When I was introduced to Kintari’s patented technology and then met the corporate leadership team, I knew that this was a special opportunity that I had to get involved with,” said Dean Aldridge. “I was so impressed by the previous network marketing experience of Terry Howlett and Rob Barnes, Kintari’s Director of Sales whose previous network marketing company topped over $20 million per year in sales. This team not only has the industry experience but the understanding of what it takes to succeed, both for Kintari and its distributors. It’s a win-win. I was also impressed by the product line made with the patented Invisicare technology, which has the capability to change the network marketing industry forever. I knew that I had discovered the perfect opportunity; the right products, the right ownership and the right compensation plan – I was in.”
The Kintari product portfolio consists of “Youth Renewed” (YR) anti-aging products to help fight the signs of aging. These products have been developed using proven anti-aging ingredients with scientific evidence of their effectiveness at reducing the look of fine lines and wrinkles resulting in youthful looking skin. These potent ingredients are powered by our patented Invisicare® technology, providing consumers with unique, effective skincare benefits which cannot be duplicated.
Kintari has an exclusive license to patented Invisicare products from its parent company Skinvisible Pharmaceuticals, Inc., a science-based research and development company. Skinvisible continues to build its worldwide patent portfolio while seeking licensees for its prescription and over-the-counter dermatology products.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. In addition, Skinvisible’s wholly-owned subsidiary Kintari will commercialize cosmeceutical and OTC products globally through a direct sales channel. www.skinvisible.com www.invisicare.com www.kintari.com
Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10k for the quarter ending June 30, 2014).
Contact:
John Pentony, Investor Relations
Ph: 972-292-8930
Email: [email protected]
John Pentony now represents Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock. John Pentony has signed a contract to as investor relations for Skinvisible, and will be paid up to eleven thousand dollars during the next twelve months should the contract go for twelve months as expected.